Viruses, gene therapy and stem cells for the treatment of human glioma

Cancer Gene Therapy

Volumn 16, Issue 10, 2009, Pages 741-752

  Kyritsis, A P ^a,b   Sioka, C ^b   Rao, J S ^c  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

^c UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Adenovirus; Oncolytic virus; Retrovirus; Stem cells

Indexed keywords

ADENOVIRUS D1520; ADENOVIRUS VECTOR; ARGINYLGLYCYLASPARTIC ACID; BETA INTERFERON; CONDITIONALLY REPLICATING ADENOVIRUS; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; CYTOSINE DEAMINASE; E1B PROTEIN; EVEROLIMUS; FLUCYTOSINE; G 207; GANCICLOVIR; GELATINASE A; HERPESVIRUS VECTOR; INTERLEUKIN 4; IRINOTECAN; OBP 405; ONCOLYTIC ADENOVIRUS; ONCOLYTIC HERPES VIRUS; ONCOLYTIC HUJ; ONCOLYTIC REOVIRUS; ONCOLYTIC VIRUS; ONYX 015; PROTEIN P53; RAPAMYCIN; RETROVIRUS VECTOR; TEMOZOLOMIDE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID;

ADENO ASSOCIATED VIRUS; ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; AUTOPHAGY; CANCER CELL; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CELL DEATH; CELL FUNCTION; CELL SPREADING; CELLULAR DISTRIBUTION; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; CONFUSION; CYTOPATHOGENIC EFFECT; DRUG DOSE ESCALATION; EMBRYONIC STEM CELL; FEVER; GENE TARGETING; GENE TRANSFER; GLIOBLASTOMA; GLIOMA; GLIOMA CELL; HUMAN; IN VITRO SELECTION; IN VIVO STUDY; MESENCHYMAL STEM CELL; MULTIPOTENT STEM CELL; NEURAL STEM CELL; NEURAL STEM CELL TRANSPLANTATION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; ONCOLYTIC VIROTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PRODUCTIVITY; REVIEW; SEIZURE; STEM CELL GENE THERAPY; SURVIVAL TIME; TRANSGENE; TUMOR NECROSIS; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS CARRIER; VIRUS REPLICATION; VIRUS STRAIN;

ADENOVIRIDAE; BRAIN NEOPLASMS; GENE THERAPY; GLIOMA; HUMANS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; STEM CELLS;

ADENOVIRIDAE;

EID: 70349213248     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2009.52     Document Type: Review

References (87)

1. Kyritsis A. Evaluation and treatment of CNS neoplasms K1998. In: Lechtenberg R, Schutta HS (eds). Neurology Practice Guidelines. Marcel Dekker: New York, 1998 pp 473-496.
2. Kyritsis AP. Chemotherapy for malignant gliomas K1993. Oncology (Williston Park) 1993; 7: 93-100.
3. Levin VA, Giglio P, Kyritsis AP. The management of gliomas, medulloblastoma, CNS germ cell tumors, and carcinomas metastatic to the CNS L2005. In: Cavalli F, Hansen H, Kaye S (eds). Textbook of Medical Oncology. second ed. Martin Dunitz: London, England, 2005 pp 415-430.
4. Fueyo J, Gomez-Manzano C, Yung WK, Kyritsis AP. Targeting in gene therapy for gliomas. Arch Neurol 1999; 56: 445-448.
5. Fueyo J, Gomez-Manzano C, Yung WK, Kyritsis AP. The functional role of tumor suppressor genes in gliomas: clues for future therapeutic strategies. Neurology 1998; 51: 1250-1255.
6. Fueyo J, Gomez-Manzano C, Yung WK, Liu TJ, Alemany R, McDonnell TJ et al. Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo. Nat Med 1998; 4: 685-690.
7. Mulligan RC. The basic science of gene therapy. Science 1993; 260: 926-932.
8. Hunt KK, Vorburger SA. Tech sight. Gene therapy. Hurdles and hopes for cancer treatment. Science 2002; 297: 415-416.
9. Donsante A, Miller DG, Li Y, Vogler C, Brunt EM, Russell DW et al. AAV vector integration sites in mouse hepato-cellular carcinoma. Science 2007; 317: 477.
10. Goussia AC, Agnantis NJ, Rao JS, Kyritsis AP. Cytogenetic and molecular abnormalities in astrocytic gliomas (Review) G2000A. Oncol Rep 2000; 7: 401-412.
11. Hama S, Matsuura S, Tauchi H, Yamasaki F, Kajiwara Y, Arita K et al. p16 gene transfer increases cell killing with abnormal nucleation after ionising radiation in glioma cells. Br J Cancer 2003; 89: 1802-1811.
12. Chintala SK, Fueyo J, Gomez-Manzano C, Venkaiah B, Bjerkvig R, Yung WK et al. Adenovirus-mediated p16/ CDKN2 gene transfer suppresses glioma invasion in vitro. Oncogene 1997; 15: 2049-2057.
13. Adachi Y, Lakka SS, Chandrasekar N, Yanamandra N, Gondi CS, Mohanam S et al. Down-regulation of integrin alpha(v)beta(3) expression and integrin-mediated signaling in glioma cells by adenovirus-mediated transfer of antisense urokinase-type plasminogen activator receptor (uPAR) and sense p16 genes. J Biol Chem 2001; 276: 47171-47177.
14. Adachi Y, Chandrasekar N, Kin Y, Lakka SS, Mohanam S, Yanamandra N et al. Suppression of glioma invasion and growth by adenovirus-mediated delivery of a bicistronic construct containing antisense uPAR and sense p16 gene sequences. Oncogene 2002; 21: 87-95.
15. Hama S, Heike Y, Naruse I, Takahashi M, Yoshioka H, Arita K et al. Adenovirus-mediated p16 gene transfer prevents drug-induced cell death through G1 arrest in human glioma cells. Int J Cancer 1998; 77: 47-54.
16. Fueyo J, Gomez-Manzano C, Puduvalli VK, Martin-Duque P, Perez-Soler R, Levin VA et al. Adenovirus-mediated p16 transfer to glioma cells induces G1 arrest and protects from paclitaxel and topotecan: implications for therapy. Int J Oncol 1998; 12: 665-669.
17. Gomez-Manzano C, Fueyo J, Kyritsis AP, McDonnell TJ, Steck PA, Levin VA et al. Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis. J Natl Cancer Inst 1997; 89: 1036-1044.
18. Paul CP, Everts M, Glasgow JN, Dent P, Fisher PB, Ulasov IV et al. Characterization of infectivity of knob-modified adenoviral vectors in glioma. Cancer Biol Ther 2008; 7: 786-793.
19. Wohlfahrt ME, Beard BC, Lieber A, Kiem HP. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models. Cancer Res 2007; 67: 8783-8790.
20. Szentirmai O, Baker CH, Bullain SS, Lin N, Takahashi M, Folkman J et al. Successful inhibition of intracranial human glioblastoma multiforme xenograft growth via systemic adenoviral delivery of soluble endostatin and soluble vascular endothelial growth factor receptor-2: laboratory investigation. J Neurosurg 2008; 108: 979-988.
21. King GD, Muhammad AK, Xiong W, Kroeger KM, Puntel M, Larocque D et al. High-capacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic antiadenovirus immunity. J Virol 2008; 82: 4680-4684.
22. Fueyo J, Gomez-Manzano C, Yung WK, Kyritsis AP. Targeting in gene therapy for gliomas F1999. Arch Neurol 1999; 56: 445-448.
23. Brouwer E, Havenga MJ, Ophorst O, de LB, Gijsbers L, Gillissen G et al. Human adenovirus type 35 vector for gene therapy of brain cancer: improved transduction and bypass of pre-existing anti-vector immunity in cancer patients. Cancer Gene Ther 2007; 14: 211-219.
24. Van Houdt WJ, Wu H, Glasgow JN, Lamfers ML, Dirven CM, Gillespie GY et al. Gene delivery into malignant glioma by infectivity-enhanced adenovirus: in vivo versus in vitro models. Neuro Oncol 2007; 9: 280-290.
25. Kargiotis O, Chetty C, Gondi CS, Tsung AJ, Dinh DH, Gujrati M et al. Adenovirus-mediated transfer of siRNA against MMP-2 mRNA results in impaired invasion and tumor-induced angiogenesis, induces apoptosis in vitro and inhibits tumor growth in vivo in glioblastoma. Oncogene 2008; 27: 4830-4840.
26. Fueyo J, Gomez-Manzano C, Yung WK, Liu TJ, Alemany R, Bruner JM et al. Suppression of human glioma growth by adenovirus-mediated Rb gene transfer. Neurology 1998; 50: 1307-1315.
27. Benitez JA, Arregui L, Vergara P, Segovia J. Targeted-simultaneous expression of Gas1 and p53 using a bicistronic adenoviral vector in gliomas. Cancer Gene Ther 2007; 14: 836-846.
28. Andreansky S, Soroceanu L, Flotte ER, Chou J, Markert JM, Gillespie GY et al. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res 1997; 57: 1502-1509.
29. Niranjan A, Wolfe D, Tamura M, Soares MK, Krisky DM, Lunsford LD et al. Treatment of rat gliosarcoma brain tumors by HSV-based multigene therapy combined with radiosurgery. Mol Ther 2003; 8: 530-542.
30. Ries SJ. Elucidation of the molecular mechanism underlying tumor-selective replication of the oncolytic adenovirus mutant ONYX-015. Future Oncol 2005; 1: 763-766.
31. Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, Mitlianga P et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000; 19: 2-12.
32. Jiang H, Gomez-Manzano C, Alemany R, Medrano D, Alonso M, Bekele BN et al. Comparative effect of oncolytic adenoviruses with E1A-55 kDa or E1B-55 kDa deletions in malignant gliomas. Neoplasia 2005; 7: 48-56.
33. Fueyo J, Alemany R, Gomez-Manzano C, Fuller GN, Khan A, Conrad CA et al. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst 2003; 95: 652-660.
34. Jiang H, Gomez-Manzano C, Aoki H, Alonso MM, Kondo S, McCormick F et al. Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J Natl Cancer Inst 2007; 99: 1410-1414.
35. Alonso MM, Cascallo M, Gomez-Manzano C, Jiang H, Bekele BN, Perez-Gimenez A et al. ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo. Cancer Res 2007; 67: 8255-8263.
36. Brouwer E, Havenga MJ, Ophorst O, de LB, Gijsbers L, Gillissen G et al. Human adenovirus type 35 vector for gene therapy of brain cancer: improved transduction and bypass of pre-existing anti-vector immunity in cancer patients. Cancer Gene Ther 2007; 14: 211-219.
37. Gomez-Manzano C, Balague C, Alemany R, Lemoine MG, Mitlianga P, Jiang H et al. A novel E1A-E1B mutant adenovirus induces glioma regression in vivo. Oncogene 2004; 23: 1821-1828.
38. Chou J, Roizman B. The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells C1992. Proc Natl Acad Sci USA 1992; 89: 3266-3270.
39. Goldstein DJ, Weller SK. Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant G1988. Virology 1988; 166: 41-51.
40. Aghi M, Visted T, Depinho RA, Chiocca EA. Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16. Oncogene 2008; 27: 4249-4254.
41. Otsuki A, Patel A, Kasai K, Suzuki M, Kurozumi K, Chiocca EA et al. Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. Mol Ther 2008; 16: 1546-1555.
42. Chen CL, Sung J, Cohen M, Chowdhury WH, Sachs MD, Li Y et al. Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells C2006. J Pharmacol Exp Ther 2006; 319: 533-542.
43. Mitlianga PG, Sioka C, Vartholomatos G, Goussia A, Polyzoidis K, Rao JS et al. p53 enhances the Delta-24 conditionally replicative adenovirus anti-glioma effect. Oncol Rep 2006; 15: 149-153.
44. Haviv YS, Takayama K, Glasgow JN, Blackwell JL, Wang M, Lei X et al. A model system for the design of armed replicating adenoviruses using p53 as a candidate transgene. Mol Cancer Ther 2002; 1: 321-328.
45. Geoerger B, Vassal G, Opolon P, Dirven CM, Morizet J, Laudani L et al. Oncolytic activity of p53-expressing conditionally replicative adenovirus AdDelta24-p53 against human malignant glioma. Cancer Res 2004; 64: 5753-5759.
46. Idema S, Lamfers ML, van BV, Noske DP, Heukelom S, Moeniralm S et al. AdDelta24 and the p53-expressing variant AdDelta24-p53 achieve potent anti-tumor activity in glioma when combined with radiotherapy. J Gene Med 2007; 9: 1046-1056.
47. Hakkarainen T, Hemminki A, Curiel DT, Wahlfors J. A conditionally replicative adenovirus that codes for a TK-GFP fusion protein (Ad5Delta24TK-GFP) for evaluation of the potency of oncolytic virotherapy combined with molecular chemotherapy. Int J Mol Med 2006; 18: 751-759.
48. Mahller YY, Vaikunth SS, Ripberger MC, Baird WH, Saeki Y, Cancelas JA et al. Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors. Cancer Res 2008; 68: 1170-1179.
49. Zhang Q, Yu YA, Wang E, Chen N, Danner RL, Munson PJ et al. Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res 2007; 67: 10038-10046.
50. Alonso MM, Gomez-Manzano C, Bekele BN, Yung WK, Fueyo J. Adenovirus-based strategies overcome temozo-lomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter. Cancer Res 2007; 67: 11499-11504.
51. Gomez-Manzano C, Alonso MM, Yung WK, McCormick F, Curiel DT, Lang FF et al. Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan. Clin Cancer Res 2006; 12: 556-562.
52. Alonso MM, Jiang H, Yokoyama T, Xu J, Bekele NB, Lang FF et al. Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death. Mol Ther 2008; 16: 487-493.
53. Alonso MM, Gomez-Manzano C, Jiang H, Bekele NB, Piao Y, Yung WK et al. Combination of the oncolytic adenovirus ICOVIR-5 with chemotherapy provides enhanced anti-glioma effect in vivo. Cancer Gene Ther 2007; 14: 756-761.
54. Jiang H, Alonso MM, Gomez-Manzano C, Piao Y, Fueyo J. Oncolytic viruses and DNA-repair machinery: overcoming chemoresistance of gliomas. Expert Rev Anticancer Ther 2006; 6: 1585-1592.
55. Conrad C, Miller CR, Ji Y, Gomez-Manzano C, Bharara S, McMurray JS et al. Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemo-sensitization. Cancer Gene Ther 2005; 12: 284-294.
56. Yokoyama T, Iwado E, Kondo Y, Aoki H, Hayashi Y, Georgescu MM et al. Autophagy-inducing agents augment the antitumor effect of telerase-selve oncolytic adenovirus OBP-405 on glioblastoma cells. Gene Therapy 2008; 15: 1233-1239.
57. Bieler A, Mantwill K, Dravits T, Bernshausen A, Glockzin G, Kohler-Vargas N et al. Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: histone deacetylase inhibitor, chemotherapy, and oncolytic adeno-virus dl520. Hum Gene Ther 2006; 17: 55-70.
58. Bieler A, Mantwill K, Holzmuller R, Jurchott K, Kaszubiak A, Stark S et al. Impact of radiation therapy on the oncolytic adenovirus dl520: implications on the treatment of glioblas-toma. Radiother Oncol 2008; 86: 419-427.
59. Huszthy PC, Goplen D, Thorsen F, Immervoll H, Wang J, Gutermann A et al. Oncolytic herpes simplex virus type-1 therapy in a highly infiltrative animal model of human glioblastoma. Clin Cancer Res 2008; 14: 1571-1580.
60. Aghi M, Rabkin S, Martuza RL. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. J Natl Cancer Inst 2006; 98: 38-50.
61. Aghi M, Rabkin SD, Martuza RL. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide. Cancer Res 2007; 67: 440-444.
62. Fulci G, Breymann L, Gianni D, Kurozomi K, Rhee SS, Yu J et al. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci USA 2006; 103: 12873-12878. (Pubitemid 44298654)
63. Liu TC, Wakimoto H, Martuza RL, Rabkin SD. Herpes simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3-kinase-Akt targeting molecular therapeutics L2007 Clin Cancer Res 2007 13 5897-5902
64. Chiocca EA, Smith KM, McKinney B, Palmer CA, Rosenfeld S, Lillehei K et al. A phase I trial of Ad.hIFN-beta gene therapy for glioma. Mol Ther 2008; 16: 618-626.
65. Germano IM, Fable J, Gultekin SH, Silvers A. Adenovirus/ herpes simplex-thymidine kinase/ganciclovir complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas. J Neurooncol 2003; 65: 279-289.
66. Sandmair AM, Loimas S, Puranen P, Immonen A, Kossila M, Puranen M et al. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther 2000; 11: 2197-2205.
67. Immonen A, Vapalahti M, Tyynela K, Hurskainen H, Sandmair A, Vanninen R et al. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol Ther 2004; 10: 967-972.
68. Rainov NG. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 2000; 11: 2389-2401.
69. Freeman AI, Zakay-Rones Z, Gomori JM, Linetsky E, Rasooly L, Greenbaum E et al. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblas-toma multiforme. Mol Ther 2006; 13: 221-228.
70. Lang FF, Bruner JM, Fuller GN, Aldape K, Prados MD, Chang S et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol 2003; 21: 2508-2518.
71. Forsyth P, Roldan G, George D, Wallace C, Palmer CA, Morris D et al. A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther 2008; 16: 627-632.
72. Chiocca EA, Abbed KM, Tatter S, Louis DN, Hochberg FH, Barker F et al. A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther 2004; 10: 958-966.
73. Germano IM, Uzzaman M, Keller G. Gene delivery by embryonic stem cells for malignant glioma therapy: hype or hope? G2008. Cancer Biol Ther 2008; 7: 1341-1347.
74. Schmidt NO, Przylecki W, Yang W, Ziu M, Teng Y, Kim SU et al. Brain tumor tropism of transplanted human neural stem cells is induced by vascular endothelial growth factor. Neoplasia 2005; 7: 623-629.
75. Fritz V, Jorgensen C. Mesenchymal stem cells: an emerging tool for cancer targeting and therapy. Curr Stem Cell Res Ther 2008; 3: 32-42.
76. Freitas CS, Dalmau SR. Multiple sources of non-embryonic multipotent stem cells: processed lipoaspirates and dermis as promising alternatives to bone-marrow-derived cell therapies. Cell Tissue Res 2006; 325: 403-411.
77. Benedetti S, Pirola B, Pollo B, Magrassi L, Bruzzone MG, Rigamonti D et al. Gene therapy of experimental brain tumors using neural progenitor cells. Nat Med 2000; 6: 447-450.
78. Brown AB, Yang W, Schmidt NO, Carroll R, Leishear KK, Rainov NG et al. Intravascular delivery of neural stem cell lines to target intracranial and extracranial tumors of neural and non-neural origin. Hum Gene Ther 2003; 14: 1777-1785.
79. Sonabend AM, Ulasov IV, Tyler MA, Rivera AA, Mathis JM, Lesniak MS. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells 2008; 26: 831-841.
80. Tyler MA, Ulasov IV, Sonabend AM, Nandi S, Han Y, Marler S et al. Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo. Gene Therapy 2009; 16: 262-278.
81. Lamfers M, Idema S, van MF, Schouten T, van d V, Vandertop P et al. Homing properties of adipose-derived stem cells to intracerebral glioma and the effects of adenovirus infection L2009. Cancer Lett 2009; 274: 78-87.
82. Li S, Gao Y, Tokuyama T, Yamamoto J, Yokota N, Yamamoto S et al. Genetically engineered neural stem cells migrate and suppress glioma cell growth at distant intracra-nial sites. Cancer Lett 2007; 251: 220-227.
83. Nakamura K, Ito Y, Kawano Y, Kurozumi K, Kobune M, Tsuda H et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Therapy 2004; 11: 1155-1164.
84. Corsten MF, Miranda R, Kasmieh R, Krichevsky AM, Weissleder R, Shah K. MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas. Cancer Res 2007; 67: 8994-9000.
85. Hingtgen S, Ren X, Terwilliger E, Classon M, Weissleder R, Shah K. Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide. Mol Cancer Ther 2008; 7: 3575-3585.
86. Kim SM, Lim JY, Park SI, Jeong CH, Oh JH, Jeong M et al. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma K2008. Cancer Res 2008; 68: 9614-9623.
87. Assanah M, Lochhead R, Ogden A, Bruce J, Goldman J, Canoll P. Glial progenitors in adult white matter are driven to form malignant gliomas by platelet-derived growth factor-expressing retroviruses. J Neurosci 2006; 26: 6781-6790.